<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/55C268C6-B70B-4CD2-9DA8-F4EE370BCA72"><gtr:id>55C268C6-B70B-4CD2-9DA8-F4EE370BCA72</gtr:id><gtr:name>Shyden Biotechnology Ltd</gtr:name><gtr:address><gtr:line1>53 CAVENDISH ROAD</gtr:line1><gtr:city>BALHAM</gtr:city><gtr:postCode>SW12 0BL</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55C268C6-B70B-4CD2-9DA8-F4EE370BCA72" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>55C268C6-B70B-4CD2-9DA8-F4EE370BCA72</gtr:id><gtr:name>Shyden Biotechnology Ltd</gtr:name><gtr:address><gtr:line1>53 CAVENDISH ROAD</gtr:line1><gtr:city>BALHAM</gtr:city><gtr:postCode>SW12 0BL</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>37480.0</gtr:offerGrant><gtr:projectCost>62634.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D97B2F13-8587-4B95-9659-2A9234CE28ED"><gtr:id>D97B2F13-8587-4B95-9659-2A9234CE28ED</gtr:id><gtr:firstName>Mahendra</gtr:firstName><gtr:surname>Deonarain</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710447"><gtr:id>7C7E806D-FAA8-42CA-8D24-EF29E2D95452</gtr:id><gtr:title>Safer activatable, anti-EGFR bispecific antibodies for metastatic colorectal cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710447</gtr:grantReference><gtr:abstractText>ShyDen Biotechnology is a start-up antibody drug discovery company based in the Open
Innovation incubator, The Stevenage Bioscience Catalyst. It is discovering and developing the
next generation of bispecific antibodies that can be switched on or off, thus carrying a new
level of molecular regulation and thus safety. This project is to take two clinically-approved
and established monoclonal antibodies and combine them in such a way as to produce a
bispecific antibody when binding of one arm controls the other. This will be aimed at
metastatic colorectal cancer, but later other solid cancers could be targeted.</gtr:abstractText><gtr:fund><gtr:end>2015-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>37480</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710447</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>